News
TEVA
41.17
+0.17%
0.07
TEVA Stock Alert: What to Know as Teva Therapeutics' Scores FDA Approval for Schizophrenia Treament
Barchart · 9h ago
Weekly Report: what happened at TEVA last week (1005-1009)?
Weekly Report · 12h ago
Teva price target raised to $50 from $40 at JPMorgan
TipRanks · 22h ago
Hospital group files lawsuit to stop 340B rebate pilot again
Seeking Alpha · 2d ago
Teva: 'Hold' On FDA Approval Of Weltruza And Pivot To Growth Strategy
Seeking Alpha · 3d ago
Midday Fly By: SpaceX buys spectrum, Delta cuts earnings guidance
TipRanks · 3d ago
Teva gains approval of monthly olanzapine injection for schizophrenia
Seeking Alpha · 3d ago
Bank of America Securities Sticks to Its Buy Rating for Teva (TEVA)
TipRanks · 3d ago
Teva announces FDA approval for Weltruza
TipRanks · 3d ago
First Tracks Biotherapeutics price target raised to $62 from $55 at Wells Fargo
TipRanks · 3d ago
Teva call volume above normal and directionally bullish
TipRanks · 5d ago
Weekly Report: what happened at TEVA last week (0928-1002)?
Weekly Report · 10/05 09:27
AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot
Seeking Alpha · 10/03 18:37
Scotiabank Keeps Their Buy Rating on Teva (TEVA)
TipRanks · 10/02 12:55
Teva announces published review on dopamine pathways in Tourette syndrome
TipRanks · 10/02 12:20
Teva announces new data for ecopipam
TipRanks · 10/02 12:20
Exxon Mobil downgraded, BP upgraded: Wall Street’s top analyst calls
TipRanks · 10/01 13:40
Piper Sandler Sticks to Its Buy Rating for Teva (TEVA)
TipRanks · 10/01 12:05
Teva, Samsung Bioepis expand strategic partnership to advance biosimilars
TipRanks · 10/01 10:20
Teva initiated with a Buy at TD Cowen
TipRanks · 10/01 09:35
More
Webull provides a variety of real-time TEVA stock news. You can receive the latest news about Teva Pharmaceutical Industries through multiple platforms. This information may help you make smarter investment decisions.
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.